The absolute number of target cells obtained after each selection and the yield of the target fraction
| . | PBMCs . | CD4/CD14/CD45RA-depleted fraction . | CD4/CD14/CD45RA-depleted CD62L+ fraction . |
|---|---|---|---|
| Cell number | 697 × 106 (558-1282 × 106) | 31.2 × 106 (23.4-38.6 × 106) | 8.8 × 106 (7.2-13.8 × 106) |
| % CD45RA−CD8+CD62L+ | 1.7 (0.4-3.3) | 16.3 (9.2-25.7) | 42.1 (22.5-55.9)* |
| Yield of CD45RA−CD8+CD62L+ cells† | 45.5% (21.3%-88.4%) | 25.2% (15.8%-55.5%) |
| . | PBMCs . | CD4/CD14/CD45RA-depleted fraction . | CD4/CD14/CD45RA-depleted CD62L+ fraction . |
|---|---|---|---|
| Cell number | 697 × 106 (558-1282 × 106) | 31.2 × 106 (23.4-38.6 × 106) | 8.8 × 106 (7.2-13.8 × 106) |
| % CD45RA−CD8+CD62L+ | 1.7 (0.4-3.3) | 16.3 (9.2-25.7) | 42.1 (22.5-55.9)* |
| Yield of CD45RA−CD8+CD62L+ cells† | 45.5% (21.3%-88.4%) | 25.2% (15.8%-55.5%) |
The majority of non-CD8+ cells were CD13+CD62L+ myeloid cells.
The yield of CD45RA−CD8+CD62L+ cells was calculated by multiplying the absolute cell number of each fraction and the proportion that were CD45RA−CD8+CD62L+, and dividing by the absolute number of CD45RA−CD8+CD62L+ cells in PBMCs × 100 (%). The data are the summary of 5 experiments.